Related Experiment Video
Updated: Jun 6, 2026
08:09
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
Age and genetic strain differences in response to chronic methylphenidate administration
Pamela B Yang1, Derly O Cuellar, Alan C Swann
1Department of Anatomy and Neurobiology, University of California, Irvine, School of Medicine, Irvine, CA 92697, USA.
Behavioural Brain Research
|November 30, 2010
Summary
Methylphenidate hydrochloride (MPD) affects adolescent and adult rats differently based on strain and dose. Higher MPD doses (2.5 and 10.0mg/kg) reveal significant differences in locomotor activity, indicating varied neuronal responses.
Area of Science:
- Neuroscience
- Pharmacology
- Animal Models
Background:
- Methylphenidate hydrochloride (MPD) is a psychostimulant for ADHD treatment.
- Adolescence is a critical neurodevelopmental period sensitive to pharmacological agents.
- Genetic variability influences drug response and the development of tolerance or sensitization.
Purpose of the Study:
- To investigate dose-response effects of MPD on locomotor activity in adolescent and adult rats.
- To compare MPD effects across Wistar-Kyoto (WKY), Spontaneously Hyperactive (SHR), and Sprague-Dawley (SD) rat strains.
- To determine if genetic variability influences MPD-induced changes in locomotion.
Main Methods:
- Repeated administration of MPD at 0.6, 2.5, or 10.0mg/kg (i.p.) in adolescent and adult rats.
- Utilized an open field assay to measure locomotor activity.
- Compared responses across WKY, SHR, and SD rat strains.
Main Results:
- Acute and chronic MPD administration produced strain- and age-specific differences in locomotor activity.
- Adult rats generally showed a more intense increase in locomotor activity than adolescents.
- Significant differences in MPD response were observed at 2.5 and 10.0mg/kg, but not 0.6mg/kg.
Conclusions:
- Rat strain and age significantly influence responses to MPD, suggesting differential effects on neuronal circuits.
- MPD affects locomotor activity differently across strains and ages, particularly at higher doses.
- Distinct locomotor indices are regulated by separate neuronal circuits, each uniquely impacted by MPD.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:30Attention-Deficit/Hyperactivity Disorder
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
01:28Human Genetics
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
The complex relationship between genetics and psychology is observable through common biological components such...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...